Gland Pharma Ltd.
Gland Pharma Ltd.

Gland Pharma Ltd.

Maintaining A Healthy Edge

Ninad Ramdasi Article rating: 3.8

With its particular acclaim for sterile injectables, oncology and ophthalmic products, the company has begun to reinforce its position on the international stage by venturing into markets like Saudi Arabia, Singapore, Israel and CIS regions.

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!
These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

Amid the heavy sell off, many quality midcaps, which have proven to be wealth creators for the investors in the past, have witnessed correction and are trading at low PE

Bhavya Rathod Article rating: 3.8

With times like these, investors shouldn’t panic and keep a close eye on the fundamentally strong companies,

Overnight Digest: Stocks to be kept an eye on May 5
Overnight Digest: Stocks to be kept an eye on May 5

Overnight Digest: Stocks to be kept an eye on May 5

India VIX zoomed 7.86 per cent at the end of Wednesday's trading session ending at 21.88.

Shreya Chaware Article rating: 4.3

On Wednesday, the domestic equity markets were driven majorly by events namely the commencement of the IPO of Life Insurance Corporation (LIC) and an increase of 40 bps in repo rate by Monetary Policy Committee (MPC).  

Overnight Digest: Stocks to keep an eye on April 22
Overnight Digest: Stocks to keep an eye on April 22

Overnight Digest: Stocks to keep an eye on April 22

Shreya Chaware Article rating: 4.5

On Thursday, the bulls took the charge and forced the benchmark indices to close on a higher note. The broader markets also replicated the benchmark indices and closed in green. 

DSIJ MINDSHARE

Mkt Commentary20-Dec, 2024

Swing Trading22-Dec, 2024

IPO Analysis20-Dec, 2024

Mindshare20-Dec, 2024

IPO Analysis20-Dec, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR